FGF21 and metabolic dysfunction-associated steatotic liver disease: The results showed that despite the presence of severe NAFLD status (Fig. 5K and L), FGF21 knockout diminished HFD-induced breast cancer tumor growth, resulting in comparable tumor volume and weight to the SFD group (Fig. 5M and N).